NCT00011986 · OUTCOME

Overall Survival

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer · Source last updated 2019-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Proportion of participants
Interval / dispersion: Not reported
Time frame: Up to 9 years

What was measured

Proportion of participants whose overall survival exceeded 5 years.

Analysis population: All enrolled participants.

Groups in this outcome

Carbo/Taxol

Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles

Carbo/Taxol/Gemcitabine

Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Gemcitabine 800 mg/m2/dIV on days 1 and 8 x 8 cycles

Carbo/Taxol/Doxil

Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Doxil 30 mg/m2 IV every other cycle on day 1 x 8 cycles

Carbo/Topotecan - Carbo/Taxol

Topotecan 1.25 mg/m2/dIV days 1-3 plus Carboplatin AUC 5 IV on day 3 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles

Carbo/Gemcitabine - Carbo/Taxol

Gemcitabine 1000 mg/m2/dIV on days 1 and 8 plus Carboplatin AUC 6 IV on day 8 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Carbo/Taxol	864
Carbo/Taxol/Gemcitabine	864
Carbo/Taxol/Doxil	862
Carbo/Topotecan - Carbo/Taxol	861
Carbo/Gemcitabine - Carbo/Taxol	861

Reported measurements

Source class 1

Values in Proportion of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Carbo/Taxol	0.35	Not reported	Not reported	Not reported	Not reported
Carbo/Taxol/Gemcitabine	0.34	Not reported	Not reported	Not reported	Not reported
Carbo/Taxol/Doxil	0.39	Not reported	Not reported	Not reported	Not reported
Carbo/Topotecan - Carbo/Taxol	0.34	Not reported	Not reported	Not reported	Not reported
Carbo/Gemcitabine - Carbo/Taxol	0.30	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
0.35
group Id
OG001
value
0.34
group Id
OG002
value
0.39
group Id
OG003
value
0.34
group Id
OG004
value
0.30

denoms

counts
group Id
OG000
value
864
group Id
OG001
value
864
group Id
OG002
value
862
group Id
OG003
value
861
group Id
OG004
value
861
units
Participants

description

Proportion of participants whose overall survival exceeded 5 years.

groups

description
Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles
id
OG000
title
Carbo/Taxol
description
Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Gemcitabine 800 mg/m2/dIV on days 1 and 8 x 8 cycles
id
OG001
title
Carbo/Taxol/Gemcitabine
description
Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Doxil 30 mg/m2 IV every other cycle on day 1 x 8 cycles
id
OG002
title
Carbo/Taxol/Doxil
description
Topotecan 1.25 mg/m2/dIV days 1-3 plus Carboplatin AUC 5 IV on day 3 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles
id
OG003
title
Carbo/Topotecan - Carbo/Taxol
description
Gemcitabine 1000 mg/m2/dIV on days 1 and 8 plus Carboplatin AUC 6 IV on day 8 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles
id
OG004
title
Carbo/Gemcitabine - Carbo/Taxol

param Type

NUMBER

population Description

All enrolled participants.

reporting Status

POSTED

time Frame

Up to 9 years

title

Overall Survival

type

PRIMARY

unit Of Measure

Proportion of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice